Rakovina Therapeutics Inc. Secures $4 Million in Strategic Financing

Rakovina Therapeutics Inc., a biopharmaceutical company specializing in AI-powered oncology drug discovery, has announced a strategic financing round of approximately $4 million. This funding is aimed at accelerating the company’s growth in the United States and enhancing its innovative cancer therapies.

The financing, announced on May 15, 2025, involves a private placement of convertible debenture units and equity units. The convertible debenture units are expected to generate gross proceeds of approximately $1.1 million, while the equity units are projected to bring in about $2.9 million. This strategic move is part of Rakovina’s broader plan to focus on US-centric growth and leverage artificial intelligence in its drug discovery processes.

In addition to the financing, Rakovina Therapeutics has also announced a share consolidation initiative. This consolidation is intended to streamline the company’s capital structure and support its ambitious growth strategy.

The company, which trades on the TSX Venture Exchange, has a market capitalization of 6,335,667 CAD. Despite recent fluctuations, with a 52-week high of 0.23 CAD and a low of 0.04 CAD, the close price on May 13, 2025, was 0.05 CAD.

Rakovina Therapeutics serves a global customer base and continues to focus on breakthrough innovations in the oncology field. The company’s strategic financing and share consolidation efforts are expected to bolster its position as a leader in AI-driven cancer therapy development.

For more information, Rakovina Therapeutics can be reached through its official website at www.rakovinatherapeutics.com .